菜单
立即预约
远程问诊
立即咨询
预约
谢谢！我们已收到您的提交！
哎呀！提交表格时出错了。
LucenceINSIGHT™ is a multi-cancer early detection (MCED) test that screens for the signal of 50 cancers through a simple blood draw. It leverages proprietary technology to amplify and identify signs of ctDNA and viruses in the bloodstream. The advanced sequencing analysis predicts signal localization.
LucenceINSIGHT™ is a multi-cancer earlydetection (MCED) tool that screens for thecirculating tumor DNA (ctDNA) of up to 50cancers in one simple blood draw.
It leverages proprietary technology to amplify and identify signs of ctDNA and viruses in the bloodstream. The advanced sequencing analysis predicts signal localization.
The result is cross examined with machine-learning to study the cancer signal profile. Utilizing data from the analysis, the test reports a presence or absence of a cancer signal. A localization signal is also derived and used to predict up to 2 sites where the cancer signal might have originated from (“Predicted Signal Localization”). The report will present the result as Predicted Signal Localization, with an accuracy of 88%.
AmpliMarkTM Upgrade (Lucence Mirror Barcodes)
Lucence's ultrasensitive amplicon-based enrichment chemistry offers high sensitivity and specificity for sequencing circulating tumor DNA, with low error rate achieved through mirror barcoding.
LucenceINSIGHT™ is based on a proprietary amplicon-based technology to screen for the signal of cancer with a specificity of 99.2%.
The test detects cancer-associated alterations circulating in blood. Advanced sequence analysis predicts the site of origin. The report will present your result as Areas of Concern, with an accuracy of 90%.
LucenceINSIGHTTM screens for cancer withlow false positives compared to tumormarker proteins.
A report is generated in 12 or 18 working days.
1. Early Detection Leads to Better Outcomes
2. Cancer is the number 1 killer.1
3. 4 in 5 cancer deaths are not covered by recommended screening.3,4
4. 5-year survival is higher with early detection.5
LucenceINSIGHT™ is recommended in conjunction with existing screening tools for:
LucenceINSIGHT™ is recommended for use in conjunction with existing screening tools for individuals without a personal history of cancer.
The test is NOT recommended for patients who:
No fasting is needed. Refrain from heavy meals.
Retrospective study shown at ASCO 2023:
Real-world experience shown at ESMO Asia 2023:
LucenceINSIGHT® Core is a multi-cancer early detection (MCED) next-generation sequencing blood test that screens for 6 cancers, accounting for >60% of cancer deaths in Asia. The test uses Lucence’s technology to detect and analyze circulating tumor DNA (ctDNA). It then identifies potential tumor location(s) with machine learning.
Clinical Assessment
Blood Tests
Urine Tests
CARDIAC SCREEN
Cytology
IMAGING
Clinical Assessment
Blood Tests
Urine Tests
Stool Test
CARDIAC SCREEN
Cytology
IMAGING
Clinical Assessment
Blood Tests
Urine Tests
Stool Test
CARDIAC SCREEN
Cytology
IMAGING
PLUS CHOOSE 2 OF
Clinical Assessment
Blood Tests
Urine Tests
Stool Test
CARDIAC SCREEN
Cytology
IMAGING
PLUS CHOOSE 3 OF
SCOPES
